



(51) International Patent Classification:
C12N 9/64 (2006.01) A61K 38/48 (2006.01)

(21) International Application Number:
PCT/US2024/022956

(22) International Filing Date:
04 April 2024 (04.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/456,916 04 April 2023 (04.04.2023) US
63/623,030 19 January 2024 (19.01.2024) US

(71) Applicant: ONCHILLES PHARMA, INC. [US/US];
9880 Campus Point Drive, Suite 420, San Diego, California
92121 (US).

(72) Inventors: TURNER, Court R.; 15830 Las Planideras,
Rancho Santa Fe, California 92067 (US). BECKER, Lev;
1507 S. Prairie Avenue, Chicago, Illinois 60605 (US). CUI,
Chang; c/o Onchilles Pharma, Inc., 9880 Campus Point Drive,
Suite 420, San Diego, California 92121 (US).

(74) Agent: ROGEL, Mark E. et al.; Cooley LLP, 1299 Penn-
sylvania Avenue, NW, Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PROTEIN COMPLEXES




FIG. 3B

(57) Abstract: Provided are pharmaceutical compositions comprising alpha-2-macroglobulin (A2M) and a serine protease protein such as porcine pancreatic elastase (PPE), which are bound together in a protein complex that retains the CD95 protease cleavage and cancer-cell killing activities of the serine protease, but sterically hinders binding of the serine protease to fibrinogen and serine protease inhibitors; and related methods of use and manufacture for treating diseases such as cancers.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
22 May 2025 (22.05.2025)